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Results: 3864 dialysis access procedures were identi-
fied; mean patient age was 60.6 15.2 years, and 53.9% of
patients were men. SSI occurred in 84 patients (2.2%), and
graft failure in 86 patients (2.2%). Risk factors associated
with SSI included obesity [OR (95%CI): 2.46 (1.57-3.84);
P0.001] and preoperative infected or open wound [OR
(95%CI): 2.29 (1.22-4.29); P0.010)] (Table 1); risk
factors for graft failure included operative time [OR
(95%CI): 2.21 (1.39-3.54); P0.001 for highest quartile
versus other] and history of disseminated cancer [OR
(95%CI): 7.36 (1.56-34.86); P0.012]. (Table 2).
Conclusions: SSI and early graft failure occur with
low incidence following dialysis access procedures.
Obesity, infected or open wound, operative time, and
disseminated cancer are risk factors for these complica-
tions.
Table 1. Surgical Site Infection: multivariate model.
Univariate p  0.01 for all covariates displayed
Variable OR (95% CI) P Value
Wound-Open/Infection 2.29 (1.22-4.29) 0.010
Obesity (BMI 30) 2.46 (1.57-3.84) 0.001
Rest pain/Gangrene 2.25 (0.76-6.66) 0.144
CHF 1.62 (0.73-3.62) 0.237
Female 1.32 (0.85-2.05) 0.225
Emergent Operation 1.51 (0.56-4.09) 0.422
Bleeding Disorder 1.43 (0.82-2.50) 0.206
Contaminated Case 1.84 (0.81-4.21) 0.146
Table 2. Graft Failure: multivariate model. Univariate
p  0.01 for all covariates displayed
Variable OR (95% CI) P Value
Operative Time (highest
quartile vs. other) 2.21 (1.39-3.54) 0.001
Disseminated Cancer 7.36 (1.56-34.86) 0.012
Rest pain/Gangrene 3.42 (0.95-11.01) 0.060
Redo Operation 0.73 (0.38-1.37) 0.323
Emergent Operation 1.53 (0.45-5.25) 0.499
General Anesthetic 1.28 (0.77-2.12) 0.342
Platelets (1000/L) 1.00 (1.00-1.01) 0.131
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Background: Lipid modifying drug therapy (LMDT)
is recommended in all patients having coronary or non-
coronary atherosclerotic disease. However, the effect of
LMDT after aortic aneurysm (AA) repair especially in the
absence of other atherosclerotic manifestations is unclear.
We examined the distribution of prevalence of LMDT
among patients undergoing AA repair and its effect on
survival in the presence and absence of other atherosclerotic
diseases.
Methods: We identified index AA repair procedures
performed between 1985 and 2010 at the University of
Alabama at Birmingham Vascular service from a prospec-
tively maintained registry. Information was collected from
health system medical charts, medical communication, and
national death indices. We assessed the predictors of prev-
alence of LMDT by univariate analysis using t-test for
continuous and chi-square test for categorical variables, and
then performed multivariate logistic regression. The sur-
vival was determined using Kaplan-Meier plots and ad-
justed hazard ratios were calculated using Cox-Proportion
regression.
Results: 2431 patients underwent AA repair proce-
dure. 13% were African American and 19% were female.
37% received LMDT and 32% died during the follow-up
period of 250 months. White race (OR-1.7, 95% CI: 1.2-
2.3), presence of other atherosclerotic disease or diabetes
(OR-2.7, 95% CI: 2.2-3.4), Pa hypertension (OR-4.2, 95%
CI: 3.3-5.4), and endovascular AA repair (OR-1.8, 95%CI:
1.5-2.2) were significant predictors of LMDT. LMDT was
associated with improved survival (Hazard Ratio-0.6, 95%
CI: 0.6-0.8) after controlling for traditional risk factors and
other atherosclerotic diseases.
Conclusions: Aggressive management of dyslipidemia
should be recommended in all irrespective of atheroscle-
rotic disease status and risk factor profile.
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